Electrochemotherapy for Breast Cancer—Results From the INSPECT Database
Autor: | J. Odili, Pietro Curatolo, Tobian Muir, Shramana Banerjee, Mohammed Keshtgar, S.H. Liew, Julie Gehl, Roberta Rotunno, Jackie Newby, Louise Wichmann Matthiessen, James Clover, Annette Klein, Francesca de Terlizzi, Eva Stauss, D. Mowatt, Eva Maria Grischke, Valerie Letulé, Alison Claire Humphreys, Karin Dahlstroem, Christian Kunte |
---|---|
Rok vydání: | 2018 |
Předmět: |
Adult
0301 basic medicine Cancer Research medicine.medical_specialty Electrochemotherapy Skin Neoplasms Palliative care Databases Factual Breast Neoplasms Bleomycin 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Breast cancer Humans Medicine Disseminated disease General anaesthesia Adverse effect Aged Aged 80 and over Antibiotics Antineoplastic business.industry Middle Aged medicine.disease Treatment Outcome 030104 developmental biology Oncology chemistry 030220 oncology & carcinogenesis Female Radiology business Progressive disease |
Zdroj: | Clinical Breast Cancer. 18:e909-e917 |
ISSN: | 1526-8209 |
Popis: | Background Cutaneous recurrence from breast cancer can pose a clinical challenge. It might be the only disease site, or could be part of disseminated disease, and often profoundly affects quality of life. Electrochemotherapy is a palliative treatment using electric pulses to locally permeabilize tumor cells and thereby significantly increase bleomycin cytotoxicity. Collaborating with the International Network for Sharing Practice on ElectroChemoTherapy (INSPECT), we consecutively and prospectively accrued data on patients treated with electrochemotherapy for cutaneous metastases from breast cancer. Patients and Methods Patients were treated with electrochemotherapy at 10 European centers. Under either local or general anaesthesia patients were treated with either local injection (1000 IU/mL intratumoral) or systemic infusion (15,000 IU/m2) of bleomycin. Results One hundred nineteen patients were included at 10 institutions in the INSPECT network. The primary location was the chest (89%), the median diameter of the cutaneous metastases was 25 mm. Ninety patients were available for response evaluation after 2 months. Complete response was observed in 45 patients (50%), partial response in 19 (21%), stable disease in 16 (18%), and progressive disease in 7 (8%). Three patients were not evaluable. Common side effects were ulceration, long-lasting hyperpigmentation, and low-grade pain. No serious adverse events were observed. Conclusion Electrochemotherapy showed high response rates after a single treatment. Electrochemotherapy has few side effects and can be used as an adjunct to systemic therapies or as a solo treatment. We therefore recommend considering electrochemotherapy for patients with cutaneous metastases. |
Databáze: | OpenAIRE |
Externí odkaz: |